Chlorambucil, Vincristine and Cytarabine (COA) Treatment of Low Grade Lymphomas

References

• Young R.C., Longo D.L., Gladstein E., et al. The treatment of indolent lymphomas: Watchful waiting vs. aggressive combined modality treatment. Semin. Haematol. 1988; 25: 11–16
   PubMed Web of Science ®Google Scholar
• Licht J.D., Bosserman L.D., Andersen J.W., et al. Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term disease-free survival. Cancer 1990; 66(4)632–639
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Smith T., Bodey G.P. Factors affecting complete response rate and survival. Cancer 1979; 44: 1983–1989
   PubMed Web of Science ®Google Scholar
• Hoppe R.T., Kushlan P., Kaplan H.S., et al. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592–598
   PubMed Web of Science ®Google Scholar
• Peterson B.A., Frizzera G., Anderson J.R., et al. Response of low-grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisone, and bleomycin (CAVBP). Proceedings of the 21st Annual Meeting of the American Society of Clinical Oncology. 1985; 3: 211
   Google Scholar
• Ezdnili E.Z., Anderson J.R., Melvin F., et al. Moderate vs. aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. Oncol 1985; 3: 769–774
   PubMed Web of Science ®Google Scholar
• Meusers P., Engelhard M., Battels H., et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: antracylcine does not improve prognosis. Haematol. Oncol. 1989; 7: 365–371
   PubMed Web of Science ®Google Scholar
• Lepage E., Sebban C., Gisselbrecht C., Coiffier B., Harousseau J.C., Bryon P.A., Boiron M. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Haematological Oncol 1990; 8: 31–39
   PubMed Web of Science ®Google Scholar
• McLaughin P., Fuller L.M., Velasquez W.S., et al. Stage III follicular lymphoma: durable remission with a combined chemotherapy-radiotherapy regimen. J. Clin. Oncol 1987; 5: 867–874
   PubMed Web of Science ®Google Scholar
• Peterson S.A., Anderson J.R., Frizzera G., Bloomfield C.D., Propert K.J., Gottlieb A.J. (1990) Combination chemotherapy prolongs survival in follicular mixed lymphoma. Proceedings of the 26th Annual Meeting of the American Society of Clinical Oncology, Washington, 1990. 9: 259
   Google Scholar
• Straus D.J., Gaynor J.J., Leiberman P.M., et al. Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment. Am. J. Med. 1986; 82: 247
   Web of Science ®Google Scholar
• Schilsky R.L. Antimetabolites. The chemotherapy source book, M.C. Perry. Williams and Wilkins, Baltimore 1992; 301–317
   Google Scholar
• Gronowitz J.S., Hagberg H., Callander C. F. R., Simonsson B. The use of deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br. J. Cancer 1983; 47: 487–495
   PubMed Web of Science ®Google Scholar
• Hagberg H., Glimelius B., Gronowitz S., Killander A., Kallander C., Scroder T. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: A multivariate analysis. Scand. J. Haematol 1984; 33: 59–67
   PubMedGoogle Scholar
• Iaffaioli R.V., Frasci G., Facchini G., et al (1990) Tumor necrosis factor: a new marker for neoplastic patients. Proceedings of the First International Congress on Debated Problems in Clinical Oncology, Rome, 1990, 66
   Google Scholar
• Carbone P., Kaplan H., Musshoff L., et al. Report of the Committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1960–1961
   Google Scholar
• Meager A., Parti S., Leung H., et al. A two-site sandwich immunoradiometric assay of human lymphotoxin with monoclonal antibodies and its applications. J. Immunol. Methods 1987; 104: 31–42
   PubMed Web of Science ®Google Scholar
• Kaplan E.S., Meier P. Non parametric estimation for incomplete observations. J. Am. Stat. Ass. 1958; 53: 457–480
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new-rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966; 50: 163–170
   PubMedGoogle Scholar
• Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 1972; 34: 187–220
   Google Scholar
• Fisher R.A., Yates F. Statistical tables for biological, agricultural and medical research. Oliver and Boyd, Edinburgh 1963
   Google Scholar
• Fisher R.A. The significance of deviations from expectation in a Poisson series. Biometrics 1950; 17–24
   Web of Science ®Google Scholar
• Wilkinson Leland. SYSTAT: The system for Statistics. SYSTAT, INC, Evanston, IL 1988
   Google Scholar
• Romaguerra J.E., McLaughin P., North L., Dixon D., et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J. Clin. Oncol. 1991; 9(5)762–769
   PubMed Web of Science ®Google Scholar
• Coiffier B., Barbier Y., Bienvenu J., et al. Increased plasma tumor necrosis factor alpha (TNF) is correlated with adverse prognostic factors and poor response to treatment in non-Hodgkin Lymphomas. Proc. Am. Soc. Clin. Oncol. 1992; 11: 338, (abstr. 1157)
   Google Scholar
• Herrmann F., Helfrich S.G., Lindemann A., Schleiermacher E., Huber Ch., Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alpha 2-b in chronic myelogenous leukemia. J. Clin. Oncol 1992; 10: 631–634
   PubMed Web of Science ®Google Scholar
• Herrmann F., Bambach T., Bonifer R., et al. The suppressive effects of recombinant human TNF on normal and malignant hematopoiesis: Synergism with interferon gamma. Int. J. Cell. Cloning 1988; 6: 241–261
   PubMedGoogle Scholar
• Gordon J. Factors and receptors regulating the survival and selection of B lymphocytes: implications for the evolution and management of follicular lymphoma. Forum 1993; 3.4: 334–340
   Google Scholar
• Digel W., Stefanic M., Schoniger W., et al. Tumor Necrosis Factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989; 73(5)1242–1246
   PubMed Web of Science ®Google Scholar
• Soubeyrau P., Eghbali H., Bonichon F., Trojani H., et al (1990) Follicular lymphomas. Prognostic and survival in a retrospective series of 281 patients. Proceedings of the 26th Annual Meeting of the American Society of Clinical Oncology, Washington, 1990. 9: 263
   Google Scholar
• Hallek M., Wanders L., Schick H.D., Busch R., et al (1990) Factors predicting the risk of progression in low and intermediate grade non-Hodgkin's lymphoma: a multivariate analysis. Proceedings of the 26th Annual Meeting of the American Society of Clinical Oncology, Washington, 1990. 9: 272
   Google Scholar
• Osterman B., Jonsson H., Lenner P., et al (1990) Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphomas. Proceedings of the 5th European Conference on Clinical Oncology, London, 1990, 154
   Google Scholar
• Coiffier B., Bastion Y., Berger F., et al (1990) The rate of histologic progression in follicular lymphomas is constant during the first years, then decreases regularly after the 6th year. Proceedings of the 26th Annual Meeting of the American Society of Clinical Oncology, Washington, 1990. 9: 261
   Google Scholar
• Garvin A.J., Simon R.M., Osborne K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphomas: 192 cases from the National Cancer Institute. Cancer 1983; 52: 393–398
   PubMed Web of Science ®Google Scholar
• Holte H., De Lange Davies C., Beiske K., et al. Ki-67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumor progression in low-grade B-cell lymphoma. Int. J. Cancer 1989; 44: 975–980
   PubMed Web of Science ®Google Scholar
• Leith C.P., Spier C.M., Grogan T.M., et al. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. J. Clin. Oncol 1992; 8: 1259–1265
   Google Scholar
• Leonard R. C. F., Hayward R.L., Prescott R.J., et al. The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Ann. Oncol 1991; 2: 655–662
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Vose J.M., et al. Prognostic factors in aggressive malignant lymphomas. Description and validation of a prognostic index that could identify patients requiring a more intensive chemotherapy. J. Clin. Oncol 1991; 9: 211–219
   PubMed Web of Science ®Google Scholar